• English
  • 繁體中文

BRIM

Beyond Research and Innovative Medicines

  • Home
  • About Us
    • Our Story
    • Our Board
    • Our Team
  • Product Pipeline
    • Timeline
    • BRM132
    • BRM421
    • BRM521
  • Partners
  • News
  • Contact Us

Our Board Members

Haishan Jang, Ph. D., MBA

BRIM Taiwan Chairman, Chief Executive Officer

Haishan has over 30 years of extensive experience in the pharmaceutical industry, including at Centocor, DuPont, and Sanofi.She directed the scientific system, process and project management in biologic Clinical Pharmacology at Centocor, with responsibilities ranging across process integration/optimization for non-clinical, clinical pharmacology, pharmacokinetics, immune response, and clinical research activities.  Haishan has made contributions to the development of a few brand-name drugs such as Uroxatral®, Tirazon®, Remicade®, Simponi® and Stelara®. Prior to the formation of BRIM Biotechnology, Inc., Haishan held positions of President at TWI Biotechnology and COO of the Supra Incubation and Integration Center (Si2C), a Taiwan government sponsored incubation center

Frank Lee, Ph. D.

BRIM Cayman Chairman

Frank has a total of more than 41 years of industrial experience associated with drug discovery/preclinical /clinical developments. He has made contributions to the development of brand-name drugs such as Naprosyn®, Anaprox®, Ticlid®, Torado®, Avodart®, Flonase®, Imitrex®, Zofran®, Sustiva® and Velcade®. He retired from Takeda as VP of DMPK, spent time at Millennium and DuPont, and also serves as the Chairman of BRIM Cayman.

Top Taiwan Venture Capital Group

Top Taiwan Venture Capital Group (TTVC) is the largest and leading venture capital management team based in Taiwan with a fund size around $400M USD. Across their 15 years of experience, TTVC has invested in more than 250 successful companies, many of which have later become TTVC’s investors and shareholders. The TTVC team is comprised of professionals with an average of more than 5 years of industry experience.  An average of over 1000 companies a year are reviewed and new investments are continuously added to TTVC’s growing portfolio, which now covers industries such as technology, biotech, renewable energy, retail, consumer durables, healthcare, and auto parts.

Yuanta Financial Holdings

Yuanta Financial Holdings is a full-service finanical institute with dominances in securities trading and investment banking businesses. Yuanta Financial Holdings emerged from a merger in 2007 between Fuhwa Financial Holding Company and Yuanta Core Pacific Securities, which was the largest securities broker for more than a decade in Taiwan. Yuanta retains the leadership in Securities related businesses in Taiwan, and offers a wide range of services including Commercial & Merchant Banking, Life & Property Insurance, Equity Research, and Investment & Asset Management, through its subsidiaries. Yuanta has extended its reach into Asia Pacific, with operations in Hong Kong, South Korea, and South East Asia countries to enhance the firm’s capability under globalization. In the future, Yuanta Financial Holdings will continue to grow its competitiveness in securities business and to achieve one of the best financial institutes in Asia, in order to provide its clients the best in class experience.

 

BioEngine Capital Inc.

BioEngine Capital Inc. is an evergreen fund and is the venture capital arm of Center Laboratories, a listed Taiwanese pharmaceutical company. The firm makes direct equity investments into venture stage companies, typically in Series A and B. The initial allocation ranges from $5 to 20 million. BioEngine focuses on therapeutics, medical devices, and other health technology. Within therapeutics, the firm considers small molecules and biologics in Oncology, CNS, pain, rare disease, and anti-infectives. The firm typically invests in preclinical projects that have proof-of-concept data and are within 2 years prior to phase 1 trial. Within medical devices, the firm is interested in innovative minimally invasive surgical tools for patient or bedside use such as point-of-care diagnostics.

Copyright © 2019 · BRIM Biotechnology, Inc. · Built by Ladebug Studios